| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 3.213 | 2.470 | 1.961 | 695 | 1.261 | 1.921 | 1.619 | 3.695 | 9.987 |
| Total Income - EUR | - | 3.213 | 2.470 | 1.961 | 695 | 1.261 | 1.921 | 1.619 | 3.695 | 9.987 |
| Total Expenses - EUR | - | 208 | 644 | 943 | 199 | 75 | 84 | 543 | 3.496 | 6.196 |
| Gross Profit/Loss - EUR | - | 3.005 | 1.826 | 1.018 | 497 | 1.186 | 1.836 | 1.077 | 198 | 3.791 |
| Net Profit/Loss - EUR | - | 2.908 | 1.752 | 959 | 476 | 1.148 | 1.785 | 1.027 | 171 | 3.025 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Roparamed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 40 | 0 | 0 | 0 | 0 | 0 | 1.215 | 383 | 1.488 |
| Current Assets | - | 3.136 | 4.865 | 5.711 | 1.872 | 3.006 | 4.715 | 5.507 | 6.393 | 8.461 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 831 | 1.187 | 949 |
| Receivables | - | 0 | 0 | 844 | 827 | 809 | 1.456 | 1.585 | 1.317 | 787 |
| Cash | - | 3.136 | 4.865 | 4.867 | 1.045 | 2.196 | 3.259 | 3.092 | 3.888 | 6.725 |
| Shareholders Funds | - | 2.953 | 4.655 | 5.528 | 1.693 | 2.809 | 4.532 | 5.574 | 5.728 | 8.721 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 223 | 211 | 183 | 179 | 196 | 183 | 1.149 | 1.048 | 1.229 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Roparamed Srl